

Balofloxacin

Catalog No: tcsc1991



Available Sizes

Size: 100mg

Size: 500mg



Specifications

CAS No:

127294-70-6

Formula:

$C_{20}H_{24}FN_3O_4$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

389.42


Product Description

Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enzyme DNA gyrase.

Target: Antibacterial; DNA gyrase.

Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea, for the treatment of urinary tract infection (UTI). Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued

development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. Following phase II trials, Choongwae bought the rights to develop balofloxacin in Korea from Chugai. Phase III trials for UTI were completed in early 2001. Balofloxacin was approved by the Korean FDA in December 2001 for UTI. In March 2002, phase II trials were underway for RTI.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!